Heron Therapeuti Net Worth
Heron Therapeuti Net Worth Breakdown | HRTX |
Heron Therapeuti Net Worth Analysis
Heron Therapeuti's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Heron Therapeuti's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Heron Therapeuti's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Heron Therapeuti's net worth analysis. One common approach is to calculate Heron Therapeuti's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Heron Therapeuti's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Heron Therapeuti's net worth. This approach calculates the present value of Heron Therapeuti's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Heron Therapeuti's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Heron Therapeuti's net worth. This involves comparing Heron Therapeuti's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Heron Therapeuti's net worth relative to its peers.
Enterprise Value |
|
To determine if Heron Therapeuti is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Heron Therapeuti's net worth research are outlined below:
| Heron Therapeuti is way too risky over 90 days horizon | |
| Heron Therapeuti appears to be risky and price may revert if volatility continues | |
| Heron Therapeuti has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 144.28 M. Net Loss for the year was (13.58 M) with profit before overhead, payroll, taxes, and interest of 88.95 M. | |
| Heron Therapeuti currently holds about 83.54 M in cash with (22.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81. | |
| Over 77.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: CM Management LLC Purchases 200,000 Shares of Heron Therapeutics, Inc. - MarketBeat |
Heron Therapeuti uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Heron Therapeuti. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Heron Therapeuti's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Heron Therapeuti's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Heron Therapeuti is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Heron Therapeuti backward and forwards among themselves. Heron Therapeuti's institutional investor refers to the entity that pools money to purchase Heron Therapeuti's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.8 M | Congress Park Capital Llc | 2024-12-31 | 2.5 M | Jw Asset Management, Llc | 2024-12-31 | 2.3 M | Tang Capital Management Llc | 2024-12-31 | 2.1 M | Orchard Capital Management, Llc | 2024-12-31 | 1.9 M | Clearline Capital Lp | 2024-12-31 | 1.8 M | New York State Common Retirement Fund | 2024-12-31 | 1.3 M | Monaco Asset Management | 2024-12-31 | 1.2 M | Renaissance Technologies Corp | 2024-12-31 | 1.2 M | Rubric Capital Management Lp | 2024-12-31 | 26.7 M | Blackrock Inc | 2024-12-31 | 8.6 M |
Follow Heron Therapeuti's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 377.78 M.Market Cap |
|
Project Heron Therapeuti's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.06) | (0.06) | |
| Return On Capital Employed | (0.08) | (0.09) | |
| Return On Assets | (0.06) | (0.06) | |
| Return On Equity | 0.40 | 0.42 |
When accessing Heron Therapeuti's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Heron Therapeuti's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Heron Therapeuti's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Heron Therapeuti's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Heron Therapeuti. Check Heron Therapeuti's Beneish M Score to see the likelihood of Heron Therapeuti's management manipulating its earnings.
Evaluate Heron Therapeuti's management efficiency
Heron Therapeuti has return on total asset (ROA) of (0.0316) % which means that it has lost $0.0316 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (24.0888) %, meaning that it created substantial loss on money invested by shareholders. Heron Therapeuti's management efficiency ratios could be used to measure how well Heron Therapeuti manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.42 in 2025, whereas Return On Tangible Assets are likely to drop (0.06) in 2025. At this time, Heron Therapeuti's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 25.3 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 14.8 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.22) | (0.21) | |
| Tangible Book Value Per Share | (0.22) | (0.21) | |
| Enterprise Value Over EBITDA | (76.19) | (72.38) | |
| Price Book Value Ratio | (6.93) | (6.58) | |
| Enterprise Value Multiple | (76.19) | (72.38) | |
| Price Fair Value | (6.93) | (6.58) | |
| Enterprise Value | 871.2 M | 914.8 M |
Understanding the operational decisions made by Heron Therapeuti management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 3.3444 | Revenue | Quarterly Revenue Growth 0.191 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Heron Therapeuti insiders, such as employees or executives, is commonly permitted as long as it does not rely on Heron Therapeuti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Heron Therapeuti insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Heron Therapeuti Corporate Filings
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 4th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 5th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 24th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Heron Therapeuti Earnings per Share Projection vs Actual
Heron Therapeuti Corporate Directors
| Kimberly Manhard | Independent Director | Profile | |
| Jeff JD | Assistant Director | Profile | |
| John Poyhonen | Independent Director | Profile | |
| Jeff Cohn | Assistant Director | Profile |
Additional Tools for Heron Stock Analysis
When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.